Enterprise Value
9.50B
Cash
1.169B
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.01%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tazverik (Tazemetostat ) Details NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma) | Approved Quarterly sales | |
Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details Progressive familial intrahepatic cholestasis | Approved Quarterly sales | |
Palovarotene Details Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease | PDUFA Approval decision | |
Odevixibat (ileal bile acid transport inhibitor) Details Alagille syndrome | PDUFA Approval decision | |
Palovarotene Details Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease | PDUFA Adcomm | |
Tazemetostat + rituximab + lenalidomide Details R/R FL (Relapsed or Refractory Follicular Lymphoma) | Phase 3 Data readout | |
Onivyde Details Cancer, Pancreatic cancer, Carcinoma | Phase 3 Data readout | |
Cabometyx Details Cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Odevixibat (ileal bile acid transport inhibitor) Details Biliary atresia, Liver disease, COVID-19 | Phase 3 Data readout | |
Tazemetostat + R-CHOP Details Follicular lymphoma, Diffuse large B cell lymphoma | Phase 2 Interim update | |
Tazemetostat + Enzalutamide Details Cancer, Prostate cancer, Castration-resistant prostate cancer | Phase 2 Interim update | |
Tazemetostat + Mosunetuzumab Details Cancer, Follicular lymphoma | Phase 1/2 Interim update |